{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:29:41Z","timestamp":1775237381642,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015273","name":"Province of Bolzano","doi-asserted-by":"publisher","award":["210\/34.1"],"award-info":[{"award-number":["210\/34.1"]}],"id":[{"id":"10.13039\/501100015273","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Private Hospital Villa Melitta"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.neuropharm.2020.108378","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T21:19:19Z","timestamp":1604611159000},"page":"108378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Celecoxib promotes survival and upregulates the expression of neuroprotective marker genes in two different in vitro models of Parkinson's disease"],"prefix":"10.1016","volume":"194","author":[{"given":"Sarah","family":"Dassati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"Schweigreiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Buechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Waldner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108378_bib1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/ng1769","article-title":"High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease","volume":"38","author":"Bender","year":"2006","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108378_bib2","doi-asserted-by":"crossref","first-page":"e1901","DOI":"10.1038\/cddis.2015.283","article-title":"Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of \u03b1-synuclein aggregates","volume":"8","author":"Bae","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2020.108378_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.toxlet.2014.01.039","article-title":"Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases\u2013a mechanistic approach","volume":"230","author":"Baltazar","year":"2014","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.neuropharm.2020.108378_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.02.008","article-title":"Cathepsin D-many functions of one aspartic protease","volume":"68","author":"Benes","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.neuropharm.2020.108378_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bbi.2019.06.028","article-title":"Neurotoxicity to dopamine neurons after the serial exposure to alcohol and methamphetamine: protection by COX-2 antagonism","volume":"81","author":"Blaker","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2020.108378_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11481-013-9435-y","article-title":"Neural and immune mechanisms in the pathogenesis of Parkinson's disease. J","volume":"8","author":"Blandini","year":"2013","journal-title":"Neuroimmune Pharmacol"},{"key":"10.1016\/j.neuropharm.2020.108378_bib7","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1742-4658.2012.08491.x","article-title":"Animal models of Parkinson's disease","volume":"279","author":"Blandini","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2020.108378_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.beem.2014.08.009","article-title":"Bridging the age spectrum of neurodegenerative storage diseases","volume":"29","author":"Boland","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"issue":"III","key":"10.1016\/j.neuropharm.2020.108378_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-002-1301-4","article-title":"Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)","volume":"249","author":"Braak","year":"2002","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108378_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson's disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2020.108378_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-8993(98)01192-5","article-title":"Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss","volume":"823","author":"Brooks","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108378_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/10715768909087943","article-title":"Cytotoxic effects of 6-hydroxydopamine, merocyanine-540 and related compounds on human neuroblastoma and hematopoietic stem cells","volume":"7","author":"Bruchelt","year":"1989","journal-title":"Free Radic. Res. Commun."},{"key":"10.1016\/j.neuropharm.2020.108378_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mds.20675","article-title":"Parkinsonism and Anderson Fabry's disease: a case report","volume":"21","author":"Buechner","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108378_bib14","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1126\/science.aam9080","article-title":"Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease","volume":"357","author":"Burbulla","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108378_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1042\/BST0330423","article-title":"Polyunsaturated fatty acids and inflammation","volume":"33","author":"Calder","year":"2005","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2020.108378_bib16","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1002\/jnr.21425","article-title":"PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity","volume":"85","author":"Carrasco","year":"2007","journal-title":"J Neurosci Research"},{"key":"10.1016\/j.neuropharm.2020.108378_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tins.2008.02.010","article-title":"Altered vesicular dopamine storage in Parkinson's disease: a premature demise","volume":"31","author":"Caudle","year":"2008","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108378_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2009.05.023","article-title":"Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions","volume":"35","author":"Chu","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108378_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrn3039","article-title":"Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates","volume":"12","author":"Collier","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108378_bib20","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.neurobiolaging.2014.01.148","article-title":"Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain","volume":"7","author":"Dassati","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2020.108378_bib21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108378_bib22","first-page":"1815","article-title":"Lysosomes and protein degradation","volume":"36","author":"Dean","year":"1977","journal-title":"Acta Biol. Med. Ger."},{"key":"10.1016\/j.neuropharm.2020.108378_bib23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4161\/auto.25044","article-title":"TFEB: pathogenic role and therapeutic target in Parkinson disease","volume":"9","author":"Decressac","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.neuropharm.2020.108378_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00000542-200502000-00026","article-title":"Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans","volume":"102","author":"Dembo","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2020.108378_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbrc.2017.04.124","article-title":"Mitocondrial adventures at the organelle society","volume":"500","author":"Diogo","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2020.108378_bib26","doi-asserted-by":"crossref","first-page":"31068","DOI":"10.1074\/jbc.M703552200","article-title":"Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D","volume":"282","author":"Eichinger","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108378_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","article-title":"Description of Parkinson's disease as a clinical syndrom","volume":"991","author":"Fahn","year":"2003","journal-title":"Ann NY Acad Sci."},{"key":"10.1016\/j.neuropharm.2020.108378_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrg1831","article-title":"Genetics of Parkinson disease: paradigm shifts and future prospects","volume":"7","author":"Farrer","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.neuropharm.2020.108378_bib29","doi-asserted-by":"crossref","first-page":"45076","DOI":"10.1038\/srep45076","article-title":"Acute and chronic mitochondrial respiratory chain deficiency differentially regulate lysosomal biogenesis","volume":"7","author":"Fern\u00e1ndez-Mosquera","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108378_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging. An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2020.108378_bib31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12264-017-0170-x","article-title":"Olfactory dysfunction as an early biomarker in Parkinson's disease","volume":"33","author":"Fullard","year":"2017","journal-title":"Neurosci Bull."},{"key":"10.1016\/j.neuropharm.2020.108378_bib32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clinimag.2015.04.002","article-title":"Positron emission tomography in spinal infections","volume":"39","author":"Georgakopoulos","year":"2015","journal-title":"Clin. Imag."},{"key":"10.1016\/j.neuropharm.2020.108378_bib33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0026-895X(25)13536-0","article-title":"Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C1300 neuroblastoma cells in vitro","volume":"14","author":"Graham","year":"1978","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108378_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pbb.2009.07.018","article-title":"Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats","volume":"94","author":"Gupta","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.108378_bib35","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1016\/j.febslet.2015.10.021","article-title":"Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease","volume":"589","author":"Haddad","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2020.108378_bib36","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1021\/cr200010h","article-title":"Prostanoid receptors","volume":"111","author":"Hirata","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.neuropharm.2020.108378_bib37","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/jnc.13412","article-title":"Mitochondrial and lysosomal biogenesis are activated following PINK1\/parkin-mediated mitophagy","volume":"136","author":"Ivankovic","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2020.108378_bib38","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1212\/WNL.42.12.2241","article-title":"New insights into the cause of Parkinson's disease","volume":"42","author":"Jenner","year":"1992","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108378_bib39","article-title":"Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein","volume":"4","author":"Jin","year":"2007","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2020.108378_bib40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/genetics\/102.4.665","article-title":"PEP4 gene function is required for expression of several vacuolar hydrolases in Saccharomyces cerevisiae","volume":"102","author":"Jones","year":"1982","journal-title":"Genetics"},{"key":"10.1016\/j.neuropharm.2020.108378_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuro.2009.12.008","article-title":"Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats","volume":"1","author":"Kalonia","year":"2010","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2020.108378_bib42","doi-asserted-by":"crossref","first-page":"9459","DOI":"10.1038\/s41598-017-09528-z","article-title":"Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype","volume":"7","author":"Kang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108378_bib43","doi-asserted-by":"crossref","first-page":"17597","DOI":"10.1073\/pnas.1209192109","article-title":"Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system","volume":"109","author":"Kirkby","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2020.108378_bib44","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/brain\/awy147","article-title":"Is Parkinson's disease a lysosomal disorder?","volume":"141","author":"Klein","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108378_bib45","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.bbabio.2015.04.010","article-title":"Mitochondria, autophagy and age-associated neurodegenerative diseases: new insights into a complex interplay","volume":"1847","author":"Lionaki","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"277","key":"10.1016\/j.neuropharm.2020.108378_bib46","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1074\/jbc.C100560200","article-title":"The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice","volume":"18","author":"Manning-Bog","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108378_bib47","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/0140-6736(90)91006-V","article-title":"Parkinson's disease","volume":"335","author":"Marsden","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108378_bib48","article-title":"\u03b1-Synucleinopathy phenotypes. Parkinsonism relat disord","volume":"1","author":"McCann","year":"2014","journal-title":"Supplement"},{"key":"10.1016\/j.neuropharm.2020.108378_bib49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.devcel.2011.07.016","article-title":"Transcriptional activation of lysosomal exocytosis promotes cellular clearance","volume":"21","author":"Medina","year":"2011","journal-title":"Dev. Cell"},{"key":"10.1016\/j.neuropharm.2020.108378_bib50","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.3923\/pjbs.2007.3853.3858","article-title":"Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease","volume":"10","author":"Moghaddam","year":"2007","journal-title":"Pakistan J. Biol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108378_bib51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuron.2009.01.033","article-title":"Interplay between cytosolic dopamine, calcium, and \u03b1-synuclein causes selective death of substantia nigra neurons","volume":"62","author":"Mosharov","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108378_bib52","article-title":"Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular \u03b1-synuclein transfer. J Clin Invest. 130","volume":"127330","author":"Musgrove","year":"2019","journal-title":"pii"},{"key":"10.1016\/j.neuropharm.2020.108378_bib53","first-page":"801","article-title":"NSAIDs ameliorate cognitive and motor impairment in a model of parkinsonism induced by chlorpromazine","volume":"30","author":"Naeem","year":"2017","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2020.108378_bib54","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00702-019-02019-7","article-title":"Neuropsychiatric aspects of Parkinson's disease","volume":"126","author":"Nagy","year":"2019","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2020.108378_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/1570163811666140127123717","article-title":"Selective cyclooxygenase inhibitors: current status","volume":"11","author":"Nandakishore","year":"2014","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.neuropharm.2020.108378_bib56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.tins.2018.11.001","article-title":"Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson's disease","volume":"42","author":"Nguyen","year":"2019","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108378_bib57","first-page":"983","article-title":"The role of autophagy in neurodegenerative disease. Nat","volume":"19","author":"Nixon","year":"2013","journal-title":"Med"},{"key":"10.1016\/j.neuropharm.2020.108378_bib58","doi-asserted-by":"crossref","first-page":"e1056332","DOI":"10.1080\/23723556.2015.1056332","article-title":"Mitophagy: in sickness and in health","volume":"3","author":"Palikaras","year":"2016","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.neuropharm.2020.108378_bib59","doi-asserted-by":"crossref","first-page":"e1006603","DOI":"10.1371\/journal.pgen.1006603","article-title":"Protecting cells by protecting their vulnerable lysosomes: identification of a new mechanism for preserving lysosomal functional integrity upon oxidative stress","volume":"13","author":"Pascua-Maestro","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.neuropharm.2020.108378_bib60","doi-asserted-by":"crossref","first-page":"28751","DOI":"10.1038\/srep28751","article-title":"Crosstalk between cellular compartments protects against proteotoxicity and extends lifespan","volume":"26","author":"Peri\u0107","year":"2016","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.neuropharm.2020.108378_bib61","article-title":"The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease","volume":"7","author":"Pissadaki","year":"2013","journal-title":"Front. Comput. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108378_bib62","first-page":"72","volume":"122","author":"Pitcairn","year":"2019","journal-title":"Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease"},{"key":"10.1016\/j.neuropharm.2020.108378_bib63","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.molmed.2016.12.003","article-title":"Mitochondrial dysfunction and neurodegeneration in lysosomal storage disorders","volume":"23","author":"Plotegher","year":"2017","journal-title":"Trends Mol. Med."},{"issue":"110","key":"10.1016\/j.neuropharm.2020.108378_bib64","article-title":"Crosstalk between lysosomes and mitochondria in Parkinson\u2019s disease","volume":"5","author":"Plotheger","year":"2017","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.neuropharm.2020.108378_bib65","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0022-2275(20)41899-1","article-title":"Localization of the major sites of rabbit apolipoprotein D gene transcription by in situ hybridization","volume":"32","author":"Provost","year":"1991","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.neuropharm.2020.108378_bib66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18632\/aging.101373","article-title":"Cross-organelle communication at the core of longevity","volume":"10","author":"Raimundo","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.neuropharm.2020.108378_bib67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-4838(00)00162-X","volume":"1482","author":"Rassart","year":"2000","journal-title":"Apolipoprotein D. Biochim Biophys Acta"},{"key":"10.1016\/j.neuropharm.2020.108378_bib68","doi-asserted-by":"crossref","first-page":"14e29","DOI":"10.1111\/j.1471-4159.2005.03508.x","article-title":"Comprehensive regional and temporal gene expression profiling of the rat brain during the first 24 h after experimental stroke identifies dynamic ischemia-induced gene expression patterns, and reveals a biphasic activation of genes in surviving tissue","volume":"96","author":"Rickhag","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2020.108378_bib69","first-page":"551e562","article-title":"Apolipoprotein D is elevated in oligodendrocytes in the peri-infarct region after experimental stroke: influence of enriched environment","volume":"28","author":"Rickhag","year":"2007","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.neuropharm.2020.108378_bib70","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.freeradbiomed.2013.04.021","article-title":"Compartmentalized oxidative stress in dopaminergic cell death induced by pesticides and complex I inhibitors: distinct roles of superoxide anion and superoxide dismutases","volume":"61","author":"Rodriguez-Rocha","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2020.108378_bib71","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.20226","article-title":"Parkinsonian signs and substantia nigra neuron density in decendents elders without PD","volume":"56","author":"Ross","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108378_bib72","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-2094-1-6","article-title":"Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease","volume":"1","author":"S\u00e1nchez-Pernaute","year":"2004","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2020.108378_bib73","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108378_bib74","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.1204592","article-title":"TFEB links autophagy to lysosomal biogenesis","volume":"332","author":"Settembre","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108378_bib76","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1021\/bi800699v","article-title":"Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species","volume":"47","author":"Sevlever","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2020.108378_bib77","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF01244786","article-title":"Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain","volume":"74","author":"Sofic","year":"1988","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2020.108378_bib78","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1046\/j.1471-4159.2000.0741605.x","article-title":"Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease","volume":"74","author":"Soto-Otero","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2020.108378_bib79","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev.genet.38.072902.092717","article-title":"Melanocytes and the microphthalmia transcription factor network","volume":"38","author":"Steingrimsson","year":"2004","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.neuropharm.2020.108378_bib80","doi-asserted-by":"crossref","first-page":"10736","DOI":"10.1074\/jbc.R112.410530","article-title":"Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease","volume":"288","author":"Surmeier","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108378_bib81","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41598-018-37400-1","article-title":"Pomegranate activates TFEB to promote autophagy-lysosomal fitness and mitophagy","volume":"9","author":"Tan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108378_bib82","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/biof.1035","article-title":"COX-2 in the neurodegenerative process of Parkinson's disease","volume":"8","author":"Teismann","year":"2012","journal-title":"Biofactors"},{"key":"10.1016\/j.neuropharm.2020.108378_bib83","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1179\/135100001101535996","article-title":"Garbage catastrophe theory of aging: imperfect removal of oxidative damage?","volume":"6","author":"Terman","year":"2001","journal-title":"Redox Rep."},{"key":"10.1016\/j.neuropharm.2020.108378_bib84","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-5793(01)02597-2","article-title":"Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease","volume":"500","author":"Uversky","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2020.108378_bib85","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.tig.2015.01.004","article-title":"Progress in unraveling the genetic etiology of Parkinson disease in a genomic era","volume":"31","author":"Verstraeten","year":"2015","journal-title":"Trends Genet."},{"key":"10.1016\/j.neuropharm.2020.108378_bib86","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jnc.13378","article-title":"Proteolytic degradation of neuropeptide Y (NPY) from head to toe: identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery","volume":"135","author":"Wagner","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2020.108378_bib87","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3751516","article-title":"Apolipoprotein D concentration in human plasma during aging and in Parkinson's disease: a cross-sectional study","author":"Waldner","year":"2018","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.neuropharm.2020.108378_bib88","first-page":"6045","article-title":"Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models","volume":"60","author":"Williams","year":"2000","journal-title":"Canc. Res."},{"key":"10.1016\/j.neuropharm.2020.108378_bib89","doi-asserted-by":"crossref","first-page":"e39598","DOI":"10.7554\/eLife.39598","article-title":"Mitochondrial biogenesis is transcriptionally repressed in lysosomal lipid storage diseases","volume":"8","author":"Yambire","year":"2019","journal-title":"Elife"},{"issue":"50","key":"10.1016\/j.neuropharm.2020.108378_bib90","doi-asserted-by":"crossref","first-page":"e5400","DOI":"10.1097\/MD.0000000000005400","article-title":"Nonmotor symptoms in patients with Parkinson disease: a cross-sectional observational study","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine (Baltim.)"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:56:04Z","timestamp":1762214164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820304469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":89,"alternative-id":["S0028390820304469"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108378","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Celecoxib promotes survival and upregulates the expression of neuroprotective marker genes in two different in vitro models of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108378"}}